Contraceptive method employing buccal delivery of steroidal active agents

Patent 6200593 Issued on March 13, 2001. Estimated Expiration Date:

July 27, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Treatment of psychosexual dysfunctions
Patent #: 4507323
Issued on: 03/26/1985
Inventor: Stern

Treatment of sexual dysfunction
Patent #: 4521421
Issued on: 06/04/1985
Inventor: Foreman

Buccal formulation
Patent #: 4755386
Issued on: 07/05/1988
Inventor: Hsiao , et al.

Buccal drug dosage form
Patent #: 4764378
Issued on: 08/16/1988
Inventor: Keith , et al.

Administration of steroid hormones
Patent #: 4877774
Issued on: 10/31/1989
Inventor: Pitha, et al.

Buccal dosage form
Patent #: 5135752
Issued on: 08/04/1992
Inventor: Snipes

Medicaments for treating erectile disorders
Patent #: 5190967
Issued on: 03/02/1993
Inventor: Riley

Transmucosal delivery of macromolecular drugs
Patent #: 5346701
Issued on: 09/13/1994
Inventor: Heiber, et al.

Transmucosal delivery of macromolecular drugs
Patent #: 5516523
Issued on: 05/14/1996
Inventor: Heiber, et al.

Controlled release nifedipine delivery device
Patent #: 5543154
Issued on: 08/06/1996
Inventor: Rork, et al.

More ...

Inventor

Place, Virgil A.

Assignee

Place; Virgil A.

Application

No. 626927 filed on 07/27/2000

US Classes:

424/435, Mouth424/434, Mucosal (e.g., nasal, etc.)424/464, Tablets, lozenges, or pills514/772.3Solid synthetic organic polymer

Examiners

Primary: Azpuru, Carlos

Attorney, Agent or Firm

International Classes

A61F 013/02
A61K 009/20
A61K 047/30

Abstract

A buccal dosage unit is provided for administering a combination of steroidal active agents to a female individual. The novel buccal drug delivery systems may be used in female hormone replacement therapy, in female contraception, to treat female sexual dysfunction, and to treat or prevent a variety of conditions and disorders which are responsive to the active agents discussed herein. The buccal dosage unit comprises a progestin, an estrogen and optionally an androgenic agent, as well as a polymeric carrier that bioerodes and provides for delivery of the active agents throughout a predetermined drug delivery period.